AstraZeneca PLC (LSE:AZN) faced a blow on Friday after Deutsche Bank analysts downgraded the pharmaceuticals giant on what they labelled a “thoroughly disappointing” end to 2023. Analysts wrote in a note that they saw shares in AstraZeneca falling over 300p on Thursday’s closing price to 9,500p, compared to previous guidance of a rise to 11,000p. This was coupled with a rating downgrade from ‘hold’ to ‘sell’ for AstraZeneca after the firm failed to impress with full-year results on Thursday. “Cash flow was ...

Astrazeneca (AZN) reported $12.02 billion in revenue for the quarter ended December 2023, representing a year-over-year increase of 7.3%. EPS of $0.73 for the same period compares to $0.69 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $12.07 billion, representing a surprise of -0.42%. The company delivered an EPS surprise of -1.35%, with the consensus EPS estimate being $0.74.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and ...

AstraZeneca PLC (NASDAQ:AZN) Q4 2023 Earnings Conference Call February 8, 2024 6:45 AM ET Company Participants Andy Barnett - Head, IR Pascal Soriot - CEO Aradhana Sarin - CFO David Fredrickson - EVP, Oncology Business Susan Galbraith - EVP, Oncology R&D Ruud Dobber - EVP, BioPharmaceuticals Business Sharon Barr - EVP, BioPharmaceuticals R&D Marc Dunoyer - CEO, Alexion Iskra Reic - EVP of Vaccines & Immune Therapies Conference Call Participants James Gordon - JP Morgan Emily Field - Barclays Matthew Weston ...

Key TakeawaysAstraZeneca PLC missed profit forecasts Thursday as its fourth-quarter sales were slowed by falling demand for COVID-19 vaccines and medicines.The drug maker's revenue was also negatively affected by generic competition in Japan for its Nexium acid reflux treatment.AstraZeneca's American Depositary Receipts (ADRs) dropped to their lowest level in 16 months after the earnings were released Thursday.AstraZeneca PLC's (AZN) American depositary receipts (ADRs) fell more than 4% Thursday after the d ...

This being Thursday morning, we see new Weekly Jobless Claims data ahead of the opening bell for trading. Initial Jobless Claims came in 2000 lower than projections to 218K, down 9K claims from the upwardly revised 227K posted the previous week. This is yet another sub-220K week, which we were routinely above from about March through early September of last year, but this remains consistent with an overall healthy labor market.Continuing Claims had more recently been drawing closer scrutiny, as last week’s ...

This being Thursday morning, we see new Weekly Jobless Claims data ahead of the opening bell for trading. Initial Jobless Claims came in 2000 lower than projections to 218K, down 9K claims from the upwardly revised 227K posted the previous week. This is yet another sub-220K week, which we were routinely above from about March through early September of last year, but this remains consistent with an overall healthy labor market.Continuing Claims had more recently been drawing closer scrutiny, as last week’s ...

Financial Highlights - Total Revenue for FY 2023 reached $45811 million, a 6% increase at CER[26] - Product Sales Gross Margin for FY 2023 was 811%, a +10 percentage points increase[26] - Operating profit for FY 2023 increased by >2x to $8193 million[26] - Core EPS for FY 2023 increased by 15% to $726[28] - Total Revenue from Oncology in FY 2023 was $184 billion, a 21% increase[40] - Total Revenue from Rare Disease in FY 2023 was $78 billion, a 12% increase[71] Growth Drivers and Future Outlook - Total Revenue ex COVID-19 increased by low teens %, specifically +15%[12] - BioPharmaceuticals CVRM FY 2023 revenue reached $106 billion, a growth of 18%[52] - BioPharmaceuticals R&I FY 2023 revenue reached $64 billion, a growth of 10%[52] - The company anticipates a low double-digit to low-teens percentage increase in both Total Revenue and Core EPS for 2024[32]

FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of February 2024 Commission File Number: 001-11960 AstraZeneca PLC 1 Francis Crick Avenue Cambridge Biomedical Campus Cambridge CB2 0AA United Kingdom Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F X Form 40-F __ Indicate by check mark if the registra ...

AstraZeneca PLC (LSE:AZN) shares fell 1.8%, wiping £2.8 billion from the value of the business, as lingering concerns on the drug maker's cost base overshadowed better than expected results and strong forward guidance. Shore Capital is hoping management can dispell these worries: "We sense there had been an element of uncertainty heading into results around how quickly the cost base could continue to evolve over the near-medium term and expect some further clarity might be provided around this during the ca ...

CAMBRIDGE, United Kingdom--(BUSINESS WIRE)--AstraZeneca: Revenue and EPS summary     FY 2023 Q4 2023       % Change   % Change $m Actual   CER1   $m Actual CER - Product Sales 43,789 2   4   11,323 5 5 - Alliance Revenue2   1,428 89   89   424 69 67 - Collaboration Revenue2 <td colspan="1" row ...